Did BioNTech beat or miss consensus estimates last quarter?

What is BioNTech's latest dividend and current dividend yield?

What is the market's earnings forecast for BioNTech next quarter?

What were the key takeaways from BioNTech’s earnings call?

What factors drove the changes in BioNTech's revenue and profit?

What does BioNTech do and what are its main business segments?

What is BioNTech's gross profit margin?

What were the key takeaways from BioNTech's earnings call?

- **Spin-off of mRNA Innovations**: New independent company to focus on next-gen mRNA, with BioNTech retaining minority stake for collaboration potential.
- **Oncology Pipeline Momentum**: 8 Phase III trials for Pumitamig expected by year-end, with 6 late-stage readouts in 2026.
- **Financial Discipline**: 2025 R&D expenses down 2% YoY; 2026 guidance reflects focus on high-impact programs.
- **COVID-19 Vaccine Transition**: Revenue decline expected as markets normalize, with U.S. competition and Europe seasonal demand driving trends.

**【CEO Summary Section】**
- BioNTech exceeded 2025 revenue guidance, ending the year with EUR 17.2 billion in cash and securities.
- Focused on oncology pipeline, including Pumitamig (PD-L1/VEGF bispecific antibody) with 8 Phase III trials expected by end-2026.
- Announced spin-off of next-generation mRNA innovations into a new independent company, retaining a minority stake.
- Acquired CureVac to strengthen RNA platform capabilities.

**【CFO Financial Commentary】**
- 2025 total revenue: EUR 2.9 billion (up 1% YoY), driven by BMS collaboration payments.
- R&D expenses: EUR 2.1 billion (down 2% YoY) due to cost-sharing with BMS and portfolio management.
- 2026 guidance: Revenue EUR 2-2.3 billion, R&D expenses EUR 2.2-2.5 billion, focusing on late-stage oncology programs.
- COVID-19 vaccine revenue expected to decline as markets normalize.

**【Q&A Highlights】**
- **New mRNA Company**: Will focus on next-gen mRNA innovations, while BioNTech retains mRNA oncology programs. No cash contribution from BioNTech; minority stake to enable collaboration opportunities.
- **Management Transition**: Ugur and Ozlem will remain until end-2026, with Supervisory Board conducting CEO/CMO search for late-stage execution expertise.
- **Pipeline Prioritization**: Shifting resources to high-impact programs like Pumitamig, ADCs, and mRNA combinations. 6 late-stage readouts expected in 2026.
- **COVID-19 Vaccine**: U.S. market more competitive; Europe transitioning to seasonal demand. Germany direct sales decline will impact top line.

BioNTech SE(BNTX)-20260310-2025 Q4 Earnings call transcript

- **Pumitamig Momentum**: SCLC Phase II data (85% ORR) supports 2025 Phase III launch; €16.7B cash fuels oncology transition. 
- **Pipeline Expansion**: mRNA immunotherapies prioritize adjuvant settings; ADCs (T-PAM, BNT324) show clinical activity in SCLC, breast cancer. 
- **Financial Discipline**: 2025 revenue guidance raised to €2.6-2.8B; R&D expenses reduced by €600M via portfolio focus. 
- **Strategic Collaboration**: BMS partnership accelerates Pumitamig development; JSC ensures aligned decision-making. 
- **Growth Catalysts**: €700M BMS collaboration; 2025 loss reflects transition to commercial oncology company. 


**【CEO Summary Section】**
- BioNTech's vision is to become a global immunotherapy powerhouse, focusing on Pumitamig (PD-L1/VEGF-A bispecific) and mRNA cancer immunotherapies. 
- Q3 2025 revenue was €1.519B, up 22% YoY, driven by €700M from BMS collaboration. 
- Pumitamig Phase III trials in small cell lung cancer (SCLC) show 85% ORR at 20mg/kg, with global data consistent with China results. 
- €16.7B cash provides flexibility for oncology transition. 

**【CMO Commentary】**
- Pumitamig Wave 1 trials progressing: SCLC Phase III (ROSETTA LUNG-01) vs. atezolizumab + chemo; TNBC Phase III initiation on track. 
- mRNA immunotherapies: BNT111 in anti-PD-1 resistant melanoma shows 18% ORR, Autogene cevumeran iNeST in adjuvant settings prioritized for low tumor burden. 
- ADC pipeline: T-PAM (HER2 ADC) Phase III in China meets PFS endpoint; BNT324 (B7H3 ADC) shows 56% ORR in SCLC. 

**【CFO Financial Update】**
- 2025 revenue guidance raised to €2.6-2.8B (vs. prior €1.7-2.2B) due to BMS collaboration. 
- R&D expenses reduced by €600M to €2.0-2.2B, reflecting portfolio prioritization. 
- SG&A guidance lowered to €550-650M; CapEx €200-250M for manufacturing. 
- Net loss €29M (Q3 2025) due to contractual dispute; 2025 loss expected as transition to commercial oncology company. 

**【Q&A Highlights】**
- **Market Differentiation**: Pumitamig's VEGF/PD-L1 dual targeting addresses MSS CRC and gastric cancer unmet needs. 
- **BLA Delays**: T-PAM (BNT323) BLA pushed to 2026 due to FDA data requests; breast cancer data expected 2026. 
- **Trial Strategy**: 3-wave approach (Establish, Expand, Elevate) balances speed-to-market with combination studies. 
- **BMS Collaboration**: JSC governs decisions; BMS leads trials with optionality for BioNTech combinations. 


BioNTech SE (BNTX) Q3 2025 Earnings Call Transcript

- **Strategic Collaboration Success**: BMS deal brings USD 3.5 billion upfront and milestone payments, accelerating BNT327's global development.
- **Oncology Pipeline Momentum**: BNT327 Phase III trials in lung cancer show promising OS data (16.8 months), with ADC combo trials underway.
- **COVID-19 Resilience**: Maintains 50%+ market share despite lower vaccination rates, preparing for variant-adapted vaccine rollout.
- **Financial Strength**: EUR 16 billion cash reserve supports oncology investments, with 2025 R&D spend guided at EUR 2.6-2.8 billion.

**【Management Opening Remarks】**
- Douglas Maffei introduced the management team, highlighting the new CFO, Ramón Zapata, and the departure of Chief Strategy Officer Ryan Richardson. The call agenda focused on oncology strategy, financial results, and collaborations.

**【CEO Summary Section】**
- CEO Ugur Sahin emphasized BioNTech's vision to become a fully integrated biopharmaceutical company, prioritizing mRNA cancer immunotherapies (FixVac & iNeST) and the bispecific antibody BNT327.
- Key achievements: acquisition of CureVac to strengthen mRNA capabilities, collaboration with BMS for BNT327, and the launch of a new variant-adapted COVID-19 vaccine with Pfizer.
- Financial resilience: maintained a fortress balance sheet with EUR 16 billion in cash, supporting oncology pipeline development.

**【CFO Financial Commentary】**
- Q2 2025 revenue: EUR 261 million (vs. EUR 129 million in Q2 2024), driven by COVID-19 vaccine sales and a one-time effect from Pfizer's shingles program opt-out.
- R&D expenses: EUR 509 million (down 13% YoY due to reprioritization of clinical trials).
- BMS collaboration: upfront payment of USD 1.5 billion, potential milestones up to USD 7.6 billion, and shared development costs (50-50). Full-year 2025 guidance: revenue EUR 1.7-2.2 billion, R&D EUR 2.6-2.8 billion.

**【CFO Financial Commentary】**
- Q2 2025 net loss: EUR 387 million (narrowed from EUR 808 million YoY) due to lower R&D and SG&A expenses.
- Cash position: EUR 16 billion, supporting oncology investments and manufacturing expansion.
- COVID-19 vaccine outlook: expects lower vaccination rates in the U.S. but maintains market leadership; preparing for variant-adapted vaccine rollout.

**【Q&A Highlights】**
- **COVID-19 Vaccine Strategy**: CFO Ramón Zapata noted continued investment in combination vaccines but expects monovalent vaccines to remain relevant for high-risk populations. CEO Ugur Sahin reaffirmed Pfizer's market leadership (over 50% global share).
- **BNT327 Development**: CMO Ozlem Tureci detailed Phase III trials in small cell lung cancer (ROSETTA Lung-01) and non-small cell lung cancer (ROSETTA Lung-02), with OS as the primary endpoint. Early data shows encouraging OS (16.8 months) in small cell lung cancer.
- **ADC Combinations**: CEO Ugur Sahin highlighted BNT327 + ADC trials (e.g., BNT325, BNT324) aiming to replace chemotherapy in regimens. Preliminary data shows manageable safety profiles and clinical activity.
- **FixVac Melanoma Trial**: CMO Ozlem Tureci confirmed ESMO 2025 presentation of efficacy data, including ORR, PFS, and OS, with plans for further development based on results.


BioNTech SE (BNTX) Q2 2025 Earnings Call Transcript

- **BNT327 Shows Promising Efficacy**: Phase 2 data in small-cell lung cancer (85.4% ORR, 16.8-month OS) and triple-negative breast cancer (73.8% ORR) support Phase 3 trials. 
- **Financial Resilience Despite Losses**: €15.9B cash position fuels oncology R&D, despite Q1 net loss of €416M. 
- **Strategic Focus on Combination Therapies**: BNT327 + ADC/cell therapy trials aim to establish new IO backbones in multiple tumor types. 
- **COVID-19 Vaccine Market Stability**: 2025 revenue expected to remain flat, driven by elderly/immunocompromised populations.

**【CEO Summary Section】**
- BioNTech reaffirms its vision to become a multi-product biopharmaceutical company, with a focus on advancing its pan-tumor oncology programs, including BNT327 (anti-PD-L1/anti-VEGF bispecific) and mRNA cancer immunotherapies (FixVac and iNeST). 
- Key updates include Phase 2 data for BNT327 in small-cell lung cancer (median OS 16.8 months) and non-small cell lung cancer (monotherapy ORR 47%), as well as Phase 1 data for BNT116 in non-small cell lung cancer showing synergistic activity with checkpoint inhibitors. 
- The company plans to submit a BLA for BNT323 (HER2 ADC) in second-line endometrial cancer by end-2025 and initiate Phase 3 trials for BNT327 in small-cell and non-small cell lung cancer later this year.

**【CMO Clinical Updates】**
- **BNT327**: 
  - Small-cell lung cancer: Phase 2 trial shows 85.4% ORR and 16.8-month median OS; Phase 3 trial (ROSETTA Lung-01) enrolling globally. 
  - Non-small cell lung cancer: Monotherapy Phase 1 trial yields 47% ORR and 13.6-month mPFS; Phase 3 trial (ROSETTA Lung-02) targeting 942 patients. 
  - Triple-negative breast cancer: Phase 2 trial demonstrates 73.8% ORR and 69.7% 18-month OS; Phase 3 trial planned for 2025H2. 
- **BNT116**: Off-the-shelf mRNA immunotherapy shows synergistic activity with cemiplimab in PD-L1+ non-small cell lung cancer patients.

**【CFO Financial Commentary】**
- Q1 2025 Results: 
  - Revenue: €183M (down 3% YoY), driven by COVID-19 vaccine sales. 
  - R&D: €526M (up 3% YoY), reflecting clinical trial investments. 
  - Net Loss: €416M (wider 32% YoY) due to R&D spending. 
  - Cash Position: €15.9B (down from €16.3B at year-end), supporting oncology pipeline. 
- 2025 Guidance: 
  - Revenue: €1.7-2.2B (down 18-30% YoY). 
  - R&D: €2.6-2.8B (up 16-22% YoY). 
  - Capital Expenditure: €250-350M.

**【Q&A Key Highlights】**
- **BNT327 Combination Strategy**: 
  - Phase 3 trials will evaluate BNT327 + chemotherapy vs. pembrolizumab + chemo in NSCLC. 
  - Exploring ADC (e.g., BNT324, BNT326) and cell therapy combinations to enhance efficacy. 
- **Tariff Impact**: 
  - Minimal near-term impact on COVID-19 vaccine business (produced in US and EU). 
  - Long-term monitoring of biopharma tariffs; potential cost increases for clinical trials. 
- **COVID-19 Vaccine Market**: 
  - Expect stable vaccination rates in 2025; 20% of US population (elderly/immunocompromised) driving demand. 
  - Tracking FDA guidance on randomized strain selection studies.


Actual			-0.2633	-0.4268	-1.0319	1.4071	5.1596	12.7721	14.3009	13.8443	15.7573	6.7596	6.8406	9.9105	2.2218	-0.8617	0.7083	2.0971	-1.4135	-3.599	0.9019	1.118	-1.8716	-1.8848	-0.1408	-0.3862
Forecast			-0.2713	-0.0647	-0.4455	-0.2099	3.4624	8.9442	12.2044	8.4598	10.1386	7.4225	3.3521	8.3246	0.2873	-0.9091	-0.6238	2.6213	-1.3415	-2.1916	-1.7415	0.4624	-2.4778	-2.6893	-1.1172	-0.1898
Surprise	0.00%	0.00%	+2.95%	-559.66%	-131.63%	+770.37%	+49.02%	+42.80%	+17.18%	+63.65%	+55.42%	-8.93%	+104.07%	+19.05%	+673.34%	+5.21%	+213.55%	-20.00%	-5.37%	-64.22%	+151.79%	+141.78%	+24.47%	+29.91%	+87.40%	-103.48%

BNTX

BNTX fundamentals

BNTX Q4 2025 Earnings

Earnings Call

You can ask Aime

BNTX

BNTX fundamentals

BNTX Q4 2025 Earnings

Earnings Call

BNTX Earnings Call Summary for Q4/20258:00 AM on Mar 10, 2026

BNTX Earnings Call Summary for Q3/20258:00 AM on Nov 3, 2025

BNTX Earnings Call Summary for Q2/20258:00 AM on Aug 4, 2025

BNTX Earnings Call Summary for Q1/20258:00 AM on May 5, 2025

BNTX Earnings Call Summary for Q4/20248:00 AM on Mar 10, 2025

You can ask Aime